Investor Devo retweeted
$NVDA Net Options Delta: +2.3M shares
Investor Devo retweeted
My God, this Presidential debate proves that we need younger presidential candidates.
Investor Devo retweeted
BriaCell is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. For additional details, visit: bit.ly/3uE9n0q $BCTX $BCTXW
Investor Devo retweeted
Details regarding the #FDA #AdComm for #NurOwn are now posted and the docket is open for public comments. Read more about the Advisory Committee Meeting September 27, 2023 Announcement - 09/27/2023 | FDA fda.gov/advisory-committees/…
Investor Devo retweeted
I, for one, believe that every member of the ALS community - patients, advocates and organizations - should be in favor of the NurOwn AdComm.
It is finally a chance to have a transparent assessment of the science and the real world evidence.
Great news for PALS biospace.com/article/brainst… $BCLI
1
104
Investor Devo retweeted
People receiving #NurOwn told @FDACBER that it halted their paralysis
🔹P2 - 2015
🔹P3 - 2017-2019
🔹RTT - 2018-2020
🔹EAP - 2021-2022
Clinical Trial Data confirms #RealWorldEvidence that #NurOwnWorked 7 yrs & 42k deaths ago
People w #ALS have a right to testify
#SomeIsEnough
Investor Devo retweeted
$ILUS Really hoping to hear something about this before or at the Annual Shareholder Meeting on Friday.
$QIND #ERT
@ILUS_INTL @BackwellJp @NicolasLink
Investor Devo retweeted
$ILUS Officially two weeks until the @ILUS_INTL Annual Shareholder Meeting in Miami.
“A storm is brewing” and “celebration” have been phrases used by the company over the past couple months.
A lot of people are waiting on execution and finalizations.
@BackwellJp @NicolasLink
Sharing with all, as many were asking about the Type A meeting:
ir.brainstorm-cell.com/2022-…
73
Investor Devo retweeted
We are concerned that @US_FDA has a different view of regulatory flexibility than CDER, and a lack of consistency between @US_FDA review divisions. We are asking for an #AdCom to debate this promising therapy, #NurOwn. iamals.org/action/sign-the-p…
Investor Devo retweeted
$ILUS ILUS Confirms Strong Third Quarter Results With Increases in Revenue and Net Profit
· Revenue: $20,419,421
· Net Profit: $1,187,494
· Assets: $77,299,258
globenewswire.com/news-relea…
$CAPC with another great product!
Investor Devo retweeted
$INTK INTK has Sales of $15.4M in the first 3 quarters of 2022 and about $6.5 million in NET INCOME. Record Sales, Record Net Income, Record Shareholders Equity 3 quarters in a row. The Middle East projects haven't even started yet! Please retweet. otcmarkets.com/otcapi/compan…
Investor Devo retweeted
Industrial Nanotech, Inc. Provides Company Update Regarding Investor Communications, Previously Announced Deals and Initiatives $INTK globenewswire.com/news-relea…
$ILUS - our majority owned subsidiary, @QualityIndCorp, has appointed @BackwellJp as its CEO to lead the integration & development of the company’s multiple acquisitions. $QIND
9
Great work $ILUS. This deserves a nice sustained run leading up to the $ERT IPO we all know is coming.
Our $ILUS Form 10 is filed: sec.gov/Archives/edgar/data/…
6
I doubt this would’ve happened without the acquisition for $QIND being complete. Great work $ILUS team!
$ILUS Appoints Investment Bank to Assist With Up-List and Associated Acquisitions finance.yahoo.com/news/ilus-…
3




















